Last reviewed · How we verify
Medical Dermatology Specialists — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Levulan® Kerastick® | Levulan® Kerastick® | marketed | Photosensitizing agent | Protoporphyrin IX (photodynamic therapy precursor) | Dermatology |
Therapeutic area mix
- Dermatology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Galderma R&D · 1 shared drug class
- Novartis · 1 shared drug class
- Photocure · 1 shared drug class
- QLT Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Medical Dermatology Specialists:
- Medical Dermatology Specialists pipeline updates — RSS
- Medical Dermatology Specialists pipeline updates — Atom
- Medical Dermatology Specialists pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Medical Dermatology Specialists — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medical-dermatology-specialists. Accessed 2026-05-16.